https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%BA%B6%E5%89%82%E5%89%8D%E6%B2%BF
溶剂前沿 - 版本历史
2026-04-17T23:13:49Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%BA%B6%E5%89%82%E5%89%8D%E6%B2%BF&diff=315663&oldid=prev
185.180.13.100：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T15:07:44Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>溶剂前沿突变</strong>（Solvent Front Mutation, SFM），是激酶靶向治疗中一种极为棘手的<strong>[[耐药机制]]</strong>。该突变发生于激酶 ATP 结合口袋的“溶剂暴露区”（Solvent-exposed region），即药物分子延伸向细胞内环境的界面处。正常情况下，该区域通常由体积较小的氨基酸（如甘氨酸 G）占据，允许药物分子结合。然而，当发生突变（通常突变为体积较大的残基，如精氨酸 R）时，会产生严重的<strong>[[空间位阻]]</strong>，直接将药物“顶”出结合口袋，导致药物失效。与深埋在口袋内部的“守门员突变”（Gatekeeper）不同，溶剂前沿突变往往需要通过设计精巧的<strong>[[大环内酯类]]</strong>（Macrocyclic）或紧凑型下一代抑制剂（如<strong>[[洛拉替尼]]</strong>、<strong>[[瑞普替尼]]</strong>）来克服。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Solvent Front Mutation</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">溶剂前沿突变 (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:Kinase_Pocket_Solvent_Front.png|100px|激酶口袋结构示意图]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">耐药的“坚盾”</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">机制分类</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">继发性耐药 (Acquired)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发生位置</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">ATP 结合口袋外缘</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">经典代表</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">ALK [[G1202R]]<br>ROS1 [[G2032R]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要后果</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">对1代/2代药物高度耐药</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">克星药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[洛拉替尼]]</strong> (3代)<br><strong>[[瑞普替尼]]</strong> (4代/新一代)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子特征</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">甘氨酸(小) → 精氨酸(大)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：从“G”到“R”的质变</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
溶剂前沿区域通常位于激酶口袋的出口。在野生型激酶中，这里往往是一个体积最小的氨基酸——<strong>甘氨酸</strong>（Glycine, G），它就像一个宽敞的“门口”，允许药物庞大的分子结构延伸出来。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>空间位阻 (Steric Hindrance)：</strong><br />
<br>当甘氨酸突变为<strong>精氨酸</strong>（Arginine, R）时，情况发生了剧变。精氨酸拥有一个庞大的带正电侧链。这个侧链像一块巨石堵在门口，物理上阻挡了克唑替尼、阿来替尼等药物的结合。</li><br />
<li style="margin-bottom: 12px;"><strong>静电排斥 (Electrostatic Repulsion)：</strong><br />
<br>除了体积变大，精氨酸的正电荷还可能与药物分子的特定基团产生静电排斥，进一步降低亲和力。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床景观：魔高一尺，道高一丈</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">大环药物的胜利</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
为了攻克溶剂前沿突变，药物化学家开发了紧凑的<strong>大环分子</strong>（Macrocycles）。这类药物呈环状结构，体积更小、刚性更强，能够灵巧地避开突变的精氨酸侧链，钻入 ATP 口袋深处。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">靶点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 25%;">溶剂前沿突变</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 55%;">治疗策略</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[ALK]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>[[G1202R]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对克唑替尼、阿来替尼、塞瑞替尼均耐药。<br>必须使用三代药 <strong>[[洛拉替尼]]</strong> (Lorlatinib)。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[ROS1]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>[[G2032R]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">ROS1 最常见的耐药原因。克唑替尼无效。<br>需使用 <strong>[[瑞普替尼]]</strong> (Repotrectinib) 或 [[他雷替尼]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[NTRK]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">G595R / G623R</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对一代 NTRK 抑制剂（拉罗替尼）耐药。<br>需使用二代药 <strong>[[瑞普替尼]]</strong> 或 Selitrectinib。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Shaw AT, Solomon BJ, Besse B, et al. (2020).</strong> <em>Lorlatinib in advanced ROS1-positive non-small-cell lung cancer.</em> <strong>[[Lancet Oncology]]</strong>. 2019;20(12):1691-1701.<br><br />
<span style="color: #475569;">[ALK/ROS1 突破]：证明了洛拉替尼通过紧凑的分子结构设计，能够克服包括 G1202R 在内的多种难治性突变。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Drilon A, Camidge DR, Lin JJ, et al. (2024).</strong> <em>Repotrectinib in ROS1-positive non-small-cell lung cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. 2024;390:118-131.<br><br />
<span style="color: #475569;">[TRIDENT-1 研究]：权威 III 期研究。证实了新一代抑制剂瑞普替尼在 ROS1 G2032R 溶剂前沿突变患者中具有显著疗效（ORR 59%），确立了其作为克唑替尼耐药后标准治疗的地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Gainor JF, Dardaei L, Yoda S, et al. (2016).</strong> <em>Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.</em> <strong>[[Cancer Discovery]]</strong>. 2016;6(10):1118-1133.<br><br />
<span style="color: #475569;">[耐药图谱]：系统性描绘了 ALK 抑制剂的耐药机制，明确指出了 G1202R 是最常见且最难克服的继发性突变。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
溶剂前沿突变 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">对比概念</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[守门员突变]]</strong> (Gatekeeper, 如 T790M, L1196M) - 位于口袋深处</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">突变共性</td><br />
<td style="padding: 10px 15px; color: #334155;">通常涉及 <strong>Gly (G)</strong> 到 <strong>Arg (R)</strong> 的置换，体积增大</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">解决思路</td><br />
<td style="padding: 10px 15px; color: #334155;">大环化 (Macrocyclization) • 缩小分子体积 • 避免与突变残基接触</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">检测手段</td><br />
<td style="padding: 10px 15px; color: #334155;">耐药后必须进行组织或液体活检 <strong>[[NGS]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
185.180.13.100